NOVAVAX INC (NVAX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does NOVAVAX INC Do?
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC (NVAX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Stanley C. Erck and employs approximately 1,990 people, headquartered in GAITHERSBURG, Maryland. With a market capitalization of $1.3B, NVAX is one of the notable companies in the Healthcare sector.
NOVAVAX INC (NVAX) Stock Rating — Reduce (April 2026)
As of April 2026, NOVAVAX INC receives a Reduce rating with a composite score of 36.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NVAX ranks #3,551 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NOVAVAX INC ranks #564 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NVAX Stock Price and 52-Week Range
NOVAVAX INC (NVAX) currently trades at $8.16. The stock lost $0.38 (4.4%) in the most recent trading session. The 52-week high for NVAX is $11.97, which means the stock is currently trading -31.8% from its annual peak. The 52-week low is $5.01, putting the stock 62.9% above its annual trough. Recent trading volume was 3.5M shares, reflecting moderate market activity.
Is NVAX Overvalued or Undervalued? — Valuation Analysis
NOVAVAX INC (NVAX) carries a value factor score of 80/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 4.31x, compared to the Healthcare sector average of 23.63x — a discount of 82%. The price-to-sales ratio is 1.23x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NVAX trades at 3.83x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, NOVAVAX INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
NOVAVAX INC Profitability — ROE, Margins, and Quality Score
NOVAVAX INC (NVAX) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -100.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 25.6% versus the sector average of -33.1%.
On a margin basis, NOVAVAX INC reports gross margins of 72.3%, compared to 71.5% for the sector. The operating margin is -72.9% (sector: -66.1%). Net profit margin stands at -77.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -83.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NVAX Debt, Balance Sheet, and Financial Health
NOVAVAX INC has a debt-to-equity ratio of -156.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.13x, indicating strong short-term liquidity. Total debt on the balance sheet is $244M. Cash and equivalents stand at $268M.
NVAX has a beta of 1.33, meaning it is more volatile than the broader market — a $10,000 investment in NVAX would be expected to move 33.1% more than the S&P 500 on any given day. The stability factor score for NOVAVAX INC is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
NOVAVAX INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, NOVAVAX INC reported revenue of $1.06B and earnings per share (EPS) of $2.72. Net income for the quarter was $301M. Gross margin was 72.3%. Operating income came in at $305M.
In FY 2025, NOVAVAX INC reported revenue of $1.12B and earnings per share (EPS) of $2.72. Net income for the quarter was $440M. Gross margin was 93.5%. Revenue grew 64.7% year-over-year compared to FY 2024. Operating income came in at $453M.
In Q3 2025, NOVAVAX INC reported revenue of $70M and earnings per share (EPS) of $-1.25. Net income for the quarter was $-202M. Gross margin was 69.5%. Revenue grew -16.6% year-over-year compared to Q3 2024. Operating income came in at $-178M.
In Q2 2025, NOVAVAX INC reported revenue of $239M and earnings per share (EPS) of $0.66. Net income for the quarter was $107M. Gross margin was 93.6%. Revenue grew -42.4% year-over-year compared to Q2 2024. Operating income came in at $101M.
Over the past 8 quarters, NOVAVAX INC has demonstrated a growth trajectory, with revenue expanding from $415M to $1.06B. Investors analyzing NVAX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NVAX Dividend Yield and Income Analysis
NOVAVAX INC (NVAX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
NVAX Momentum and Technical Analysis Profile
NOVAVAX INC (NVAX) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
NVAX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, NOVAVAX INC (NVAX) ranks #564 out of 838 stocks based on the Blank Capital composite score. This places NVAX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing NVAX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NVAX vs S&P 500 (SPY) comparison to assess how NOVAVAX INC stacks up against the broader market across all factor dimensions.
NVAX Next Earnings Date
No upcoming earnings date has been announced for NOVAVAX INC (NVAX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NVAX? — Investment Thesis Summary
The quantitative profile for NOVAVAX INC suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 80/100 suggests attractive pricing relative to fundamentals. High volatility (stability score 36/100) increases portfolio risk.
In summary, NOVAVAX INC (NVAX) earns a Reduce rating with a composite score of 36.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NVAX stock.
Related Resources for NVAX Investors
Explore more research and tools: NVAX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NVAX head-to-head with peers: NVAX vs AZN, NVAX vs SLGL, NVAX vs VMD.